9:00 AM - 10:40 AM
[27PO7-am1-08] Analysis of the relationship between safety concerns in RMP at the time of drug approval and addition to clinically significant adverse reaction in the package inserts after approval
A password that applicants have been notified of is required to view abstracts.
If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.
We will reply after confirming that you were a participant.
Thank you for your understanding.